0.7233
-0.0897
(-11.06%)
As of 2:45:55 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, CEO & Director | 792.88k | -- | 1980 |
| Mr. Andrew R. Neill M.B.A. | Chief Financial Officer | 603.96k | -- | 1986 |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer | 695.24k | -- | 1959 |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer | 567.4k | -- | 1974 |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | -- | -- | 1976 |
| Ms. Casi DeYoung | Chief Business Officer | 523.48k | -- | 1971 |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Mr. George Fromm Ph.D. | Co-Chief Scientific Officer | -- | -- | -- |
| Mr. Suresh de Silva Ph.D. | Co-Chief Scientific Officer | -- | -- | -- |
| Ms. Kelli Collin M.S. | Senior Vice President of Quality | -- | -- | -- |
Shattuck Labs, Inc.
500 West 5th Street
Suite 1200
Austin, TX 78701
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 44
Description
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Corporate Governance
Shattuck Labs, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 30, 2025 at 12:30 PM UTC - May 5, 2025 at 12:30 PM UTC
Shattuck Labs, Inc. Earnings Date
Recent Events
Related Tickers
IKNA Ikena Oncology, Inc.
1.1300
-5.83%
KYMR Kymera Therapeutics, Inc.
21.71
-8.36%
SPRB Spruce Biosciences, Inc.
0.2900
-0.92%
TRML Tourmaline Bio, Inc.
12.68
-3.38%
RNTX Rein Therapeutics Inc.
1.7200
+1.18%
FHTX Foghorn Therapeutics Inc.
3.3900
+7.62%
CCCC C4 Therapeutics, Inc.
1.2800
-6.91%
ACTU Actuate Therapeutics, Inc. Common stock
6.73
-6.66%
GLUE Monte Rosa Therapeutics, Inc.
3.7150
-4.50%
SYRE Spyre Therapeutics, Inc.
12.87
-8.04%